To help cover the $4M equity requirement, once they file the BLA they are able to capitalize commercial grade Leronlimab which will bolster our assets on the balance sheet to help meet this need (under prelaunch inventory rules). NP has said commercial product is currently $50M and expects it to be $100M by end of year, but this is misleading as he is referencing $120K price, but capitalization will be at cost which will likely be closer to $7-15M (depending on what the cost basis is). I think the Samsung cost is around 3.1% of the stated $120K price, but current manufacturer is likely higher than Samsung.